Historical biib News Stories
Biogen's Leqembi Win, Vanqua Deal, Q3 Headwinds Up
Biogen (BIIB) saw three clear catalysts this week: Health Canada approved lecanemab (LEQEMBI®) for early Alzheimer’s, Biogen inked an exclusive deal with Vanqua Bio for a preclinical oral C5aR1 antagonist, and Q3 results prompted a trimmed full-year earnings outlook. These developments expand commercial reach and pipeline diversity but introduce near-term financial pressure that investors should weigh.
Biogen Beats Q3 but Cuts Guidance - Stock Rebounds
Biogen reported better-than-expected Q3 results but trimmed full-year guidance, announced a strategic licensing deal, and saw analyst upgrades—driving a rebound in BIIB shares amid mixed near-term signals.